Chronic Kidney Disease Anemia Management: What Should Be Done?

被引：1
|
作者：
Szczech, Lynda Anne [1 ]
机构：
[1] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA
来源：
BLOOD PURIFICATION | 2011年 / 31卷 / 1-3期
关键词：
Anemia; Chronic kidney disease; Hemoglobin; INDEPENDENT RISK-FACTORS; RENAL-INSUFFICIENCY; EPOETIN-ALPHA; TRIAL; DEATH;
D O I：
10.1159/000321852
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A transition in the approach to anemia management in nephrology occurred when randomized trials demonstrated that higher hemoglobin targets do not result in better outcomes and may arguably cause harm. Contradicting the speculative conclusions drawn based on earlier observational data, this has resulted in hypotheses regarding the cause of these seemingly disparate but substantively similar messages. The renal community now must struggle with how to incentivize quality care and maximize patient quality of life while minimizing the real safety signal of which we are now aware. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：186 / 188
页数：3
相关论文
共 50 条
  • [41] WHAT SHOULD AND SHOULD NOT BE DONE WITH A WHITLOW
    KIRSCH, JM
    BAUX, S
    REVUE DE MEDECINE, 1982, 23 (41): : 2209 - 2211
  • [42] Understanding hypertriglyceridemia What should be done? Should something be done?
    Berent, Theresa
    Derfler, Kurt
    Berent, Robert
    KARDIOLOGE, 2021, 15 (05): : 509 - 518
  • [43] Reading in the classroom. What is done, what should be done and what can be done
    Moreiro, Julian
    REVISTA DE EDUCACION, 2011, (354): : 353 - 353
  • [44] Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study
    Tadao Akizawa
    Hirofumi Makino
    Seiichi Matsuo
    Tsuyoshi Watanabe
    Enyu Imai
    Kosaku Nitta
    Yasuo Ohashi
    Akira Hishida
    Clinical and Experimental Nephrology, 2011, 15 : 248 - 257
  • [45] Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study
    Akizawa, Tadao
    Makino, Hirofumi
    Matsuo, Seiichi
    Watanabe, Tsuyoshi
    Imai, Enyu
    Nitta, Kosaku
    Ohashi, Yasuo
    Hishida, Akira
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (02) : 248 - 257
  • [46] Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease
    Hudson, JQ
    Sameri, RM
    PHARMACOTHERAPY, 2002, 22 (09): : 141S - 149S
  • [47] Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
    Cases, Aleix
    Isabel Egocheaga, M.
    Tranche, Salvador
    Pallares, Vicente
    Ojeda, Raquel
    Luis Gorriz, Jose
    Maria Portoles, Jose
    NEFROLOGIA, 2018, 38 (01): : 8 - 12
  • [48] Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
    Cases, Aleix
    Isabel Egocheaga, M.
    Tranche, Salvador
    Pallares, Vicente
    Ojeda, Raquel
    Luis Gorriz, Jose
    Maria Portoles, Jose
    ATENCION PRIMARIA, 2018, 50 (01): : 60 - 64
  • [49] Anemia management in chronic kidney disease: Intravenous iron steps forward
    Coyne, Daniel W.
    Auerbach, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (05) : 311 - 312
  • [50] Anemia Management Considering the Pathophysiology of Elderly Chronic Kidney Disease Patients
    Kuragano, Takahiro
    Mizusaki, Kousuke
    Kimura, Tomoko
    Nakanishi, Takeshi
    CKD-ASSOCIATED COMPLICATIONS: PROGRESS IN THE LAST HALF CENTURY, 2019, 198 : 135 - 143
12345